Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-02-26 Board/Management Inform…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
公告本公司董事辭任
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's board of directors, specifically the resignation of a director and plans for a replacement. It includes details such as the resignation date, the position affected, and the process for nomination of a new director. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2025-02-26 Chinese
114年02月法人說明會簡報 — 179520250219E001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Lotus Pharmaceutical, covering its business overview, growth strategy, management team, manufacturing facilities, R&D capabilities, product pipeline, and market expansion plans. It includes forward-looking statements, financial metrics like revenue and EPS trends, and strategic initiatives. The content is structured as a corporate presentation with charts, pictures, and business highlights aimed at investors or stakeholders. There is no indication that this is a formal regulatory filing such as an annual report (10-K), quarterly report (IR), or earnings release (ER). It is not an announcement of a report publication or a certification. The document fits the description of an Investor Presentation (IP), which focuses on financials, strategy, and market position in a detailed manner.
2025-02-19 Chinese
114年02月法人說明會簡報 — 179520250219M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation about 美時製藥公司 (a pharmaceutical company), dated October 2024. It includes extensive information on company milestones, revenue and EPS trends, management team, business segments, geographic operations, manufacturing facilities, R&D capabilities, product pipelines, and strategic outlook. The content is forward-looking and strategic, with financial data and operational details, but it is structured as a presentation rather than a formal regulatory filing or report. There is no indication that this is an official annual or quarterly report, audit report, earnings release, or regulatory filing. The presence of slides, pictures, and forward-looking statements strongly suggests this is an investor presentation designed to inform investors about the company's business, strategy, and financial performance. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-02-19 Chinese
114年02月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor presentation event, including date, time, location, and links to presentation materials in Chinese and English. It specifically mentions a '法人說明會' which translates to 'investor presentation' or 'analyst meeting'. The document length is short (702 characters) and it provides links to presentation files rather than containing detailed financial data or full reports. Therefore, this document is best classified as an Investor Presentation (IP).
2025-02-19 Chinese
本公司受邀參加Morgan Stanley舉辦之Taiwan Discovery Forum - Spotlight on Taiwan Non-Tech
Regulatory Filings Classification · 90% confidence The document is a brief announcement about the company (1795 美時) participating in a Morgan Stanley event called Taiwan Discovery Forum - Spotlight on Taiwan Non-Tech. It includes details about the date, time, and location of a scheduled investor presentation (法人說明會). The text does not contain any financial statements or detailed financial data, but rather an announcement of an upcoming investor presentation event. The document length is short (742 characters), and it serves as a notification rather than the presentation itself. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included here, the announcement is about the event. However, since the document is short and only announces the event, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about the event and does not contain the presentation materials themselves. Given the short length and nature of the content, Regulatory Filings (RNS) is the best fit with high confidence.
2025-02-18 Chinese
114年2月變更登記
Share Issue/Capital Change Classification · 95% confidence The document is a brief disclosure from a listed company (美時) providing details about its capital stock, including authorized capital, paid-in capital, and changes such as cancellation of restricted employee shares. The document is very short (852 characters) and contains no financial statements or detailed analysis. It appears to be a regulatory announcement about capital structure details rather than a full report. There is no indication of a full annual or interim report, audit report, or earnings release. The content fits best with a Share Issue/Capital Change announcement, as it details capital stock changes and approvals.
2025-02-17 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.